WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 585011
CAS#: 57568-80-6
Description: U 37883A is an antagonist of vascular ATP-sensitive potassium channel openers.
MedKoo Cat#: 585011
Name: U 37883A
CAS#: 57568-80-6
Chemical Formula: C21H36ClN3O
Exact Mass: 381.2547
Molecular Weight: 381.989
Elemental Analysis: C, 66.03; H, 9.50; Cl, 9.28; N, 11.00; O, 4.19
Synonym: U 37883A; U37883A; U-37883A; PNU 37883; PNU37883; PNU-37883
IUPAC/Chemical Name: 4-Morpholinecarboximidamide, N-cyclohexyl-N'-tricyclo(3.3.1.1(3,7))dec-1-yl-, monohydrochloride
InChi Key: FZALCKUJYZCDOX-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H35N3O.ClH/c1-2-4-19(5-3-1)22-20(24-6-8-25-9-7-24)23-21-13-16-10-17(14-21)12-18(11-16)15-21;/h16-19H,1-15H2,(H,22,23);1H
SMILES Code: [H]Cl.N1(/C(NC2CCCCC2)=N\C3(C4)CC5CC4CC(C5)C3)CCOCC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 381.989 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Tomoda T, Yunoki T, Naito S, Ito Y, Teramoto N. Multiple actions of U-37883A, an ATP-sensitive K+ channel blocker, on membrane currents in pig urethra. Eur J Pharmacol. 2005 Nov 7;524(1-3):1-10. Epub 2005 Oct 19. PubMed PMID: 16242124.
2: Guillemare E, Honore E, De Weille J, Fosset M, Lazdunski M, Meisheri K. Functional receptors in Xenopus oocytes for U-37883A, a novel ATP-sensitive K+ channel blocker: comparison with rat insulinoma cells. Mol Pharmacol. 1994 Jul;46(1):139-45. PubMed PMID: 8058048.
3: Humphrey SJ, Ludens JH. K-ATP-blocking diuretic PNU-37883A reduces plasma renin activity in dogs. J Cardiovasc Pharmacol. 1998 Jun;31(6):894-903. PubMed PMID: 9641474.
4: Kovalev H, Quayle JM, Kamishima T, Lodwick D. Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A. Br J Pharmacol. 2004 Mar;141(5):867-73. Epub 2004 Feb 2. PubMed PMID: 14757705; PubMed Central PMCID: PMC1574259.
5: Meisheri KD, Humphrey SJ, Khan SA, Cipkus-Dubray LA, Smith MP, Jones AW. 4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexylhydrochloride (U-37883A): pharmacological characterization of a novel antagonist of vascular ATP-sensitive K+ channel openers. J Pharmacol Exp Ther. 1993 Aug;266(2):655-65. PubMed PMID: 8355199.
6: Teramoto N. Pharmacological Profile of U-37883A, a Channel Blocker of Smooth Muscle-Type ATP-Sensitive K Channels. Cardiovasc Drug Rev. 2006 Spring;24(1):25-32. Review. PubMed PMID: 16939631.
7: Humphrey SJ, Ludens JH, Perricone SC, Skaletzky LL, Graham BE, Zins GR. Diuretic activity of N'-disubstituted morpholinoguanidine analogs of U-37883A in rats and dogs. Methods Find Exp Clin Pharmacol. 1995 May;17(4):255-66. PubMed PMID: 7475512.
8: Makowski P, Szewczyk A, Jasińska R, Pikuła S. An antagonist of ATP-regulated potassium channels, the guanidine derivative U-37883A, stimulates the synthesis of phosphatidylserine in rat liver endoplasmic reticulum membranes. FEBS Lett. 1997 Jun 9;409(2):292-6. PubMed PMID: 9202164.
9: Löffler-Walz C, Quast U. Interaction of the diuretics torasemide and U-37883A with the K(ATP) channel in rat isolated aorta. Naunyn Schmiedebergs Arch Pharmacol. 1998 Aug;358(2):230-7. PubMed PMID: 9750009.
10: Wellman GC, Barrett-Jolley R, Köppel H, Everitt D, Quayle JM. Inhibition of vascular K(ATP) channels by U-37883A: a comparison with cardiac and skeletal muscle. Br J Pharmacol. 1999 Oct;128(4):909-16. PubMed PMID: 10556925; PubMed Central PMCID: PMC1571709.
11: Ohrnberger CE, Khan SA, Meisheri KD. Synergistic effects of glyburide and U-37883A, two structurally different vascular ATP-sensitive potassium channel antagonists. J Pharmacol Exp Ther. 1993 Oct;267(1):25-30. PubMed PMID: 8229751.
12: DeWitt BJ, Cheng DY, McMahon TJ, Marrone JR, Champion HC, Kandowitz PJ. Effects of U-37883A, a vascular selective KATP+ channel antagonist, in the pulmonary and hindlimb circulation. Am J Physiol. 1996 Dec;271(6 Pt 1):L924-31. PubMed PMID: 8997262.
13: Lin YJ, Chen X, Freedman JE. U-37883A potently inhibits dopamine-modulated K+ channels on rat striatal neurons. Eur J Pharmacol. 1998 Jul 10;352(2-3):335-41. PubMed PMID: 9716371.
14: Szewczyk A, Wójcik G, Jabłonowska A, Nałecz. Guanidine derivative U-37883A, inhibits mitochondrial K+ uniport. Pol J Pharmacol. 1995 Jul-Aug;47(4):339-44. PubMed PMID: 8616514.
15: Clark MA, Lawson JA, Ludens JH. The natriuretic activity of the K+ channel blocker U-37883A displays an ADH-dependence. Methods Find Exp Clin Pharmacol. 1998 Mar;20(2):115-23. PubMed PMID: 9604853.
16: Teramoto N, Aishima M, Zhu HL, Tomoda T, Yunoki T, Takahashi-Yanaga F, Brading AF, Ito Y. Effects of U-37883A on intracellular Ca2+ -activated large-conductance K+ channels in pig proximal urethral myocytes. Eur J Pharmacol. 2004 Dec 3;506(1):1-7. PubMed PMID: 15588618.
17: Humphrey SJ, Smith MP, Cimini MG, Buchanan LV, Gibson JK, Khan SA, Meisheri KD. Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines. Methods Find Exp Clin Pharmacol. 1996 May;18(4):247-60. PubMed PMID: 8803957.
18: Turzo M, Vaith J, Lasitschka F, Weigand MA, Busch CJ. Role of ATP-sensitive potassium channels on hypoxic pulmonary vasoconstriction in endotoxemia. Respir Res. 2018 Feb 13;19(1):29. doi: 10.1186/s12931-018-0735-x. PubMed PMID: 29433570; PubMed Central PMCID: PMC5810061.
19: Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I. K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries. Br J Pharmacol. 2008 May;154(1):72-81. doi: 10.1038/bjp.2008.86. Epub 2008 Mar 10. PubMed PMID: 18332850; PubMed Central PMCID: PMC2438990.
20: Kaye AD, Skonieczny BD, Kaye AJ, Harris ZI, Luk EJ. An Analysis of Responses to Defibrotide in the Pulmonary Vascular Bed of the Cat. Am J Ther. 2016 May-Jun;23(3):e757-65. doi: 10.1097/MJT.0000000000000010. PubMed PMID: 24368612.
